Difference between revisions of "BL22 immunotoxin (CAT-3888)"

Latest revision as of 14:33, 28 February 2024

No longer in clinical development. Related to GCR-8015/CAT-8015, which have increased affinity to CD22.

General information

Class/mechanism: Recombinant anti-CD22 immunotoxin fusion protein comprised of a murine anti-CD22 antibody fragment (disulphide-linked Fv, dsFv) and Pseudomonas exotoxin PE38. BL22 binds to CD22 positive cells and is endocytosed, resulting in intracellular release of the toxin and cell death.

The original manufacturer was acquired in 2005.^[1] Development of this drug was discontinued in 2008, at which time it was superseded by the more potent and less toxic Moxetumomab pasudotox (HA22).

Preliminary data

Hairy cell leukemia

Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, Pastan I. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001 Jul 26;345(4):241-7. link to original article PubMed
Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH, Pastan I. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol. 2009 Jun 20;27(18):2983-90. Epub 2009 May 4. link to original article link to PMC article PubMed

Also known as

Code names: CAT-3888, GCR-3888

References

↑ Cambridge Antibody Technology Group PLC (CATG) Acquires Oncology Product Candidates From Genencor International, Inc.

[1] Cambridge Antibody Technology Group PLC (CATG) Acquires Oncology Product Candidates From Genencor International, Inc.

[1]

@@ Line 1: / Line 1: @@
-'''In clinical trials.'''  Also known as GCR-3888.  Related to GCR-8015/CAT-8015, which have increased affinity to CD22.
+'''No longer in clinical development. Related to GCR-8015/CAT-8015, which have increased affinity to CD22.'''
 ==General information==
-Class/mechanism: Recombinant anti-CD22 immunotoxin fusion protein comprised of a murine anti-CD22 antibody fragment (disulphide-linked Fv, dsFv) and Pseudomonas exotoxin PE38.  BL22 binds to CD22 positive cells and is endocytosed, resulting in intracellular release of the toxin and cell death.
+Class/mechanism: Recombinant anti-CD22 immunotoxin fusion protein comprised of a murine anti-CD22 antibody fragment (disulphide-linked Fv, dsFv) and Pseudomonas exotoxin PE38. BL22 binds to CD22 positive cells and is endocytosed, resulting in intracellular release of the toxin and cell death.
-The original manufacturer was acquired in 2005.<ref>[http://www.biospace.com/news_print.aspx?NewsEntityId=1132 Cambridge Antibody Technology Group PLC  (CATG) Acquires Oncology Product Candidates From Genencor International, Inc.]</ref> Development of this drug was discontinued in 2008, at which time it was superseded by the more potent and less toxic [[Moxetumomab pasudotox (HA22)]].
+The original manufacturer was acquired in 2005.<ref>[http://www.biospace.com/news_print.aspx?NewsEntityId=1132 Cambridge Antibody Technology Group PLC (CATG) Acquires Oncology Product Candidates From Genencor International, Inc.]</ref> Development of this drug was discontinued in 2008, at which time it was superseded by the more potent and less toxic [[Moxetumomab pasudotox (HA22)]].
 ==Preliminary data==
+===[[Hairy cell leukemia]]===
+# Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, Pastan I. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001 Jul 26;345(4):241-7. [https://doi.org/10.1056/NEJM200107263450402 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11474661/ PubMed]
+# Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH, Pastan I. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol. 2009 Jun 20;27(18):2983-90. Epub 2009 May 4. [https://doi.org/10.1200/jco.2008.20.2630 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc2702232/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19414673/ PubMed]
-===[[Hairy cell leukemia]]===
+==Also known as==
-# '''Abstract:''' R. J. Kreitman, W. H. Wilson, M. Stetler-Stevenson, P. Noel, I. Pastan. [http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=26&abstractID=3999 Long term follow-up of BL22 in cladribine-resistant hairy cell leukemia.] 2004 ASCO Annual Meeting abstract 6624.
+*'''Code names:''' CAT-3888, GCR-3888
-# '''Abstract:''' R. J. Kreitman, W. H. Wilson, M. Stetler-Stevenson, P. Noel, D. J. FitzGerald, I. Pastan. [http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=34304 Phase II trial of CAT-3888 (BL22) in chemo-resistant hairy cell leukemia.] 2007 ASCO Annual Meeting abstract 7095.
-# Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH, Pastan I. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol. 2009 Jun 20;27(18):2983-90. Epub 2009 May 4. [http://jco.ascopubs.org/content/27/18/2983.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19414673 PubMed]
 ==References==
 <references/>
-[[Category:Drug index]]
+[[Category:Drugs]]
-[[Category:Chemotherapy]]
+[[Category:Intravenous medications]]
-[[Category:Intravenous chemotherapy]]
-[[Category:Antibody medications]]
 [[Category:Immunotoxin]]
-[[Category:Anti-CD22 antibodies]]
+[[Category:Anti-CD22 immunotoxins]]
+[[Category:Recombinant medications]]
-[[Category:Discontinued]]
+[[Category:Halted drugs]]